SRRK - Scholar Rock Holding Corp logo

SRRK

Scholar Rock Holding Corp

Scholar Rock Holding Corporation develops biopharmaceuticals targeting neuromuscular diseases like spinal muscular atrophy. Its pipeline includes monoclonal antibodies aimed at activating growth factors, with therapies in various clinical trial stages.

⚕️ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago $1,363today

Score Overview

1 Year
Score
Net Growth-8.11%
Net TrendShrank
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score1.4
Net Growth-210.01%
Net Trend20%
Net Income Consistency
Rev Growth-100.00%
Rev Trend20%
Revenue Consistency
All Time
Score
Net Growth-6x
Net Trend13%
Net Income Consistency
Rev Growth
Rev Trend38%
Revenue Consistency

See the full market ranking →

Scholar Rock Holding Corp fundamental performance

Between 2020 and 2025, revenue declined from $ 15M to $ 0.00 and net income went from -$ 84M to -$ 377M. Revenue increased in 1 of those 5 years; net income in 1.

Scholar Rock Holding Corp currently holds a 5-year HDB Score of 1.4 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 53.82
1 Year2025-08-12
$ 32.2067.14%
5 Years2021-08-12
$ 39.4936.29%
All Time2018-05-24
$ 15.50247.23%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 408M$ 492M
2025$ 0.00-$ 377M$ 367M
2024$ 0.00-$ 246M$ 437M
2023$ 0.00-$ 165M$ 279M
2022$ 33M-$ 131M$ 315M
2021$ 18M-$ 131M$ 252M
2020$ 15M-$ 84M$ 341M
2019$ 20M-$ 49M$ 157M
IPO2018$ 0.00-$ 49M$ 175M

Explore beyond SRRK

You're looking at Scholar Rock Holding Corp. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies